title: Up-Regulation of Plasma miR-23b is Associated with Poor Prognosis of Gastric Cancer.
abstract: BACKGROUND
  Gastric cancer (GC) is a common malignant disease and microRNAs (miRNAs) have been shown to play important roles in GC tumorigenesis. As the clinical outcome of GC is closely correlated with the clinical stage at the time of diagnosis, early detection and prevention are crucial. This study was designed to evaluate the expression level of plasma miR-23b in patients with GC and investigate the relationship between plasma miR-23b expression level and the prognosis of GC.
  
  
  METHODS
  We recruited 138 patients diagnosed with GC and 50 healthy volunteers. Quantitative real-time PCR (qRT-PCR) was performed to evaluate the expression level of plasma miR-23b in all participants. The association between miR-23b expression and clinicopathological factors as well as survival rates was analyzed. Receiver operator curve (ROC) analysis was carried out to evaluate the diagnostic performance of plasma miR-23b for GC.Univariate and multivariate Cox regression analyses were conducted to determine whether plasma miR-23b was an independent predictor of survival.
  
  
  RESULTS
  The expression levels of miR-23b were upregulated in plasma samples from GC patients (P<0.01) and were significantly associated with T stage, distant metastasis, and differentiation. Significantly shorter 5-year overall survival (OS) and disease-free survival (DFS) were observed in patients with higher expression of the miR-23b (P<0.01). The area under the curve (AUC) of high expression of plasma miR-23b to diagnose GC was 0.80 (95% CI: 0.74-0.86, P<0.001). Multivariate analysis revealed that enhanced expression of plasma miR-23b was an independent predictor of OS (P=0.015) and DFS (P=0.004).
  
  
  CONCLUSIONS
  Our results indicated that plasma miR-23b was overexpressed in GC patients and high plasma miR-23b expression was associated with poor clinical outcome. Thus, plasma miR-23b may serve as a potential diagnostic biomarker and therapeutic target for GC.
authors.affiliation: Division of Gastroenterology, The Second Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Kun
authors.initials: K
authors.lastname: Zhuang
authors.affiliation: Division of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi, China (mainland).
authors.forename: Kun
authors.initials: K
authors.lastname: Han
authors.affiliation: Division of Gastroenterology, Xi'an Central Hospital, Xi'an, Shaanxi, China (mainland).
authors.forename: Hailing
authors.initials: H
authors.lastname: Tang
authors.affiliation: Division of Gastroenterology, The Second Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Xiaoran
authors.initials: X
authors.lastname: Yin
authors.affiliation: Division of Gastroenterology, The Second Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Jun
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Division of Gastroenterology, The Second Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Xin
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Division of Gastroenterology, The Second Affiliated Hospital Xi'an Jiaotong University, Xi'an, Shaanxi, China (mainland).
authors.forename: Lingxia
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000368:Aged; D018572:Disease-Free Survival; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000097:blood / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D015999:Multivariate Analysis; D011379:Prognosis; D012680:Sensitivity and Specificity; D013274:Stomach Neoplasms / Q000097:blood / Q000175:diagnosis / Q000235:genetics* / Q000473:pathology; D015854:Up-Regulation / Q000235:genetics*
chemical_list: C552430:MIRN23a microRNA, human; D035683:MicroRNAs
references.citation: N Engl J Med. 2006 Jul 6;355(1):11-20
references.pmid: 16822992
references.citation: Virchows Arch. 2008 Jan;452(1):1-10
references.pmid: 18040713
references.citation: Nat Rev Genet. 2009 Oct;10(10):704-14
references.pmid: 19763153
references.citation: Oncogene. 2010 Sep 2;29(35):4914-24
references.pmid: 20562915
references.citation: Zhonghua Yu Fang Yi Xue Za Zhi. 2010 May;44(5):390-7
references.pmid: 20654226
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Clin Chim Acta. 2012 Jul 11;413(13-14):1058-65
references.pmid: 22387599
references.citation: Cancer Res. 2012 Dec 15;72(24):6435-46
references.pmid: 23074286
references.citation: PLoS One. 2012;7(11):e50203
references.pmid: 23189187
references.citation: Int J Mol Sci. 2012 Oct 01;13(10):12544-55
references.pmid: 23202912
references.citation: Nucleic Acids Res. 2013 May 1;41(10):5400-12
references.pmid: 23580553
references.citation: Front Biosci (Landmark Ed). 2013 Jun 01;18:803-10
references.pmid: 23747848
references.citation: J Gastroenterol. 2014 Jun;49(6):1011-25
references.pmid: 23800944
references.citation: Nat Rev Mol Cell Biol. 2014 Aug;15(8):509-24
references.pmid: 25027649
references.citation: Int J Cancer. 2015 Mar 1;136(5):E359-86
references.pmid: 25220842
references.citation: Med Sci Monit. 2014 Sep 18;20:1668-74
references.pmid: 25230738
references.citation: Tumour Biol. 2014 Dec;35(12):12119-25
references.pmid: 25416437
references.citation: Int J Clin Exp Pathol. 2014 Dec 01;7(12):8833-40
references.pmid: 25674252
references.citation: Int J Cancer. 2015 Sep 15;137(6):1269-78
references.pmid: 25765901
references.citation: Tumour Biol. 2015 Sep;36(9):6973-83
references.pmid: 25861021
references.citation: Cell Death Dis. 2015 May 21;6:e1766
references.pmid: 25996293
references.citation: Oncotarget. 2015 Jul 20;6(20):18012-26
references.pmid: 26041881
references.citation: PLoS One. 2015 Jun 29;10(6):e0130996
references.pmid: 26121640